C-021

C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [35S]GTPγS from binding to the receptor with an IC50 of 18 nM[1].

Product Specifications

CAS Number

[864289-85-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

CCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/c-021.html

Purity

99.95

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 80°C) |Ethanol : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

COC1=CC2=NC(N3CCC(N4CCCCC4)CC3)=NC(NC5CCCCCC5)=C2C=C1OC

Molecular Formula

C27H41N5O2

Molecular Weight

467.65

Precautions

H302, H315, H319

References & Citations

[1]Yokoyama K, et al. Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines. Bioorg Med Chem. 2009 Jan 1;17 (1) :64-73.|[2]Matthew McMillin, et al. Neuronal CCL2 is upregulated during hepatic encephalopathy and contributes to microglia activation and neurological decline. J Neuroinflammation. 2014 Jul 10;11:121.